Reliance Trust Co. of Delaware bought a new position in shares of Mylan NV (NASDAQ:MYL) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 11,178 shares of the company’s stock, valued at approximately $317,000.
Other institutional investors have also modified their holdings of the company. Standard Life Aberdeen plc grew its stake in shares of Mylan by 6.7% in the third quarter. Standard Life Aberdeen plc now owns 268,287 shares of the company’s stock worth $9,820,000 after purchasing an additional 16,877 shares during the last quarter. Man Group plc bought a new stake in shares of Mylan in the third quarter worth $4,743,000. Mackenzie Financial Corp grew its stake in shares of Mylan by 19.3% in the third quarter. Mackenzie Financial Corp now owns 32,113 shares of the company’s stock worth $1,175,000 after purchasing an additional 5,202 shares during the last quarter. Teachers Advisors LLC grew its stake in shares of Mylan by 1.0% in the third quarter. Teachers Advisors LLC now owns 2,099,625 shares of the company’s stock worth $76,846,000 after purchasing an additional 21,416 shares during the last quarter. Finally, Nordea Investment Management AB bought a new stake in shares of Mylan in the third quarter worth $916,000. 83.69% of the stock is currently owned by institutional investors.
Shares of NASDAQ MYL traded down $0.02 during trading on Wednesday, hitting $19.65. 6,561,995 shares of the company traded hands, compared to its average volume of 6,243,454. Mylan NV has a fifty-two week low of $19.14 and a fifty-two week high of $42.50. The firm has a market capitalization of $10.13 billion, a P/E ratio of 4.29, a P/E/G ratio of 1.02 and a beta of 1.44. The company has a current ratio of 1.51, a quick ratio of 0.85 and a debt-to-equity ratio of 1.20.
Mylan (NASDAQ:MYL) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.03. Mylan had a net margin of 2.14% and a return on equity of 18.96%. The firm had revenue of $2.50 billion for the quarter, compared to analyst estimates of $2.70 billion. During the same quarter in the prior year, the business earned $0.96 earnings per share. The business’s quarterly revenue was down 7.0% compared to the same quarter last year. Equities research analysts forecast that Mylan NV will post 4.28 EPS for the current year.
Several analysts recently weighed in on the stock. Mizuho reissued a “neutral” rating on shares of Mylan in a research note on Thursday, January 31st. Wells Fargo & Co reduced their price objective on shares of Mylan from $40.00 to $33.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 27th. BMO Capital Markets boosted their price objective on shares of Mylan to $40.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 27th. They noted that the move was a valuation call. Sanford C. Bernstein lowered shares of Mylan from an “outperform” rating to a “market perform” rating and set a $33.00 target price on the stock. in a report on Wednesday, February 27th. Finally, BTIG Research dropped their target price on shares of Mylan to $35.00 and set a “buy” rating on the stock in a report on Wednesday, February 27th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the stock. Mylan presently has an average rating of “Buy” and a consensus target price of $37.35.
In other news, insider Paul Campbell sold 11,533 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $27.50, for a total transaction of $317,157.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.81% of the stock is currently owned by corporate insiders.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Featured Article: Debt-To-Equity Ratio
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.